Slingshot members are tracking this event:

Ardelyx, Inc. Announces the Initiation of a Three Part Phase 3 Clinical Trial Evaluating RDX7675 In Patients with Hyperkalemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ARDX Community voting in process
KERX Community voting in process

Additional Information

Management Comment The study will enroll patients with hyperkalemia who are taking RAASi medications. The trial will include three parts: Part A will be a single-blind study in which all subjects receive RDX7675 for four weeks; Part B will be an eight-week, double-blind, placebo-controlled, randomized withdrawal study; and Part C is an open-label, long-term safety study for subjects from Parts A and B. The primary endpoint for Part A is serum potassium change from Part A baseline, and the primary endpoint for Part B is serum potassium change from Part B baseline (RDX7675 versus placebo).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 03, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rdx7675, Potassium Binder, Hyperkalemia, Phase 3